Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
21 févr. 2019 08h30 HE
|
Cytokinetics, Incorporated; Amgen, Servier
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today...
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
20 févr. 2019 07h30 HE
|
ARCA biopharma, Inc.
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
11 déc. 2018 08h30 HE
|
MyoKardia, Inc.
MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure...
GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions
12 nov. 2018 08h30 HE
|
ARCA biopharma, Inc.
AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring with implanted devices...
CHF Solutions to Release Educational Webinar Highlighting Use of Aquadex FlexFlow® System in Post-Cardiovascular Surgery Featuring Noted Cardiovascular Surgeon, Daniel Beckles, MD, PhD
08 nov. 2018 09h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), today announced that it will release an educational webinar featuring the clinical use of the Aquadex...
ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
05 nov. 2018 08h30 HE
|
ARCA biopharma, Inc.
Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc....
ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
18 sept. 2018 08h30 HE
|
ARCA biopharma, Inc.
Gencaro potentially the first genetically-targeted treatment for heart failure patients at risk for atrial fibrillationPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that...
CHF Solutions, Inc. to Attend the 22nd Annual Scientific Meeting of the Heart Failure Society of America
11 sept. 2018 08h00 HE
|
CHF Solutions, Inc.
EDEN PRAIRE, Minn., Sept. 11, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today it will be attending the 22nd Annual Scientific Meeting of the Heart Failure Society of...
Advancements in Medical Devices Contributing to the Growth of Left Ventricular Assist Device Market to Grow at a CAGR of 10.5% during 2018-2024
16 août 2018 05h38 HE
|
Energias Market Research
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- The global left ventricular assist device (LVADs) market is expected to grow significantly from USD 1,024 million in 2017 to USD 2,043 million in 2024, at...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...